Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Carbon Monoxide
Therapeutic Area : Hematology
Study Phase : Phase I
Sponsor : National Heart, Lung, and Blood Institute
Deal Size : $3.0 million
Deal Type : Funding
Details : The funding will be used by the company through a Phase 2a clinical study of HBI-002, an oral low dose carbon monoxide therapeutic candidate in patients with sickle cell disease (SCD).
Brand Name : HBI-002
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 20, 2023
Lead Product(s) : Carbon Monoxide
Therapeutic Area : Hematology
Highest Development Status : Phase I
Sponsor : National Heart, Lung, and Blood Institute
Deal Size : $3.0 million
Deal Type : Funding
Lead Product(s) : Carbon Monoxide
Therapeutic Area : Hematology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Hillhurst Biopharmaceuticals Announces Completion Of Last Patient Last Visit In Phase 1 Clinical Trial Of HBI-...
Details : HBI-002, is an oral drug product candidate of low dose CO, with an administration route designed to enable chronic use in a home setting for patients suffering from sickle cell disease.
Brand Name : HBI-002
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 23, 2023
Lead Product(s) : Carbon Monoxide
Therapeutic Area : Hematology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Carbon Monoxide
Therapeutic Area : Genetic Disease
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Hillhurst's lead product, HBI-002, is an oral drug product candidate of low dose CO, with an administration route designed to enable chronic use in a home setting for patients suffering from sickle cell disease.
Brand Name : HBI-002
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 27, 2021
Lead Product(s) : Carbon Monoxide
Therapeutic Area : Genetic Disease
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?